What Cyclacel Pharmaceuticals does

Cyclacel Pharmaceuticals (now Bio Green Med Solution, Inc.) is a publicly traded clinical-stage biopharmaceutical company developing oral therapies for cancers and other critical diseases based on cancer cell cycle biology, epigenetics, and mitosis biology. The company's lead product candidate is Plogosertib (CYC140), a proprietary PLK1 inhibitor being developed for esophageal cancer and acute leukemia, with peer-reviewed therapeutic potential presented at AACR (April 2017) and EORTC-NCI-AACR (December 2016). The company has historically operated with no approved products and no commercial product revenue, instead relying on recurring dilutive financings — including a $1.3 million registered direct offering in December 2023, an $8.0 million private placement in April-May 2024, a $2.1 million raise in November 2024, a $1.0 million raise in March 2025, and a $3.0 million convertible preferred placement in June 2025 — to extend cash runway.

In May 2025, the company executed a Share Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd., a Malaysia-based fire protection products and services company established in 1982. Following the expected August 2025 close, Cyclacel rebranded as Bio Green Med Solution, Inc., repositioning itself as a diversified holding company with operational headquarters in Kuala Lumpur, Malaysia. Post-transaction, legacy Cyclacel stockholders own approximately 80% of the combined entity. The consolidated company now operates two segments: a fire safety division (fire equipment, foam systems, fire-resistant doors, PPE, safety apparel) and a biopharmaceutical division anchored on Plogosertib. Leadership includes Paul McBarron as Executive Vice President, CFO and COO (a director since 2006), and the company has announced a further acquisition of Future NRG for June 2026, signaling continued inorganic diversification.

Name

Cyclacel Pharmaceuticals

Legal name

Bio Green Med Solution, Inc.

Website

https://cyclacel.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Bio Green Med Solution (formerly Cyclacel Pharmaceuticals) is a clinical-stage biopharmaceutical company developing cancer therapies based on cell cycle biology, now diversified into fire protection products through its acquisition of Malaysia-based Fitters Sdn. Bhd.

Ownership category

akta.pro rank

Headquarters

HQ city

Kuala Lumpur

HQ country

Malaysia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Others

Marketing channels3 records

Core offering

Cyclacel Pharmaceuticals (now Bio Green Med Solution, Inc.) is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology, with lead candidate Plogosertib (CYC140), a novel PLK1 inhibitor for esophageal cancer and acute leukemia. Following the 2025 acquisition of Fitters Sdn. Bhd., the company also supplies fire protection products and services including fire equipment, foam systems, fire resistant doors, and personal protective equipment.

Product overview

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. The company operates as a pioneer in cancer cell cycle biology, with its primary product candidate being Plogosertib, a PLK1 inhibitor targeting cancer cell division pathways. The company has also expanded into fire safety products through its acquisition of Fitters Sdn. Bhd., creating a diversified portfolio spanning oncology and industrial safety sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Plogosertib (CYC140) A novel PLK1 inhibitor drug candidate being developed by Cyclacel/Bio Green Med Solution for the treatment of esophageal cancer and acute leukemia, with potential applications across multiple cancer indications.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• FITTERS Diversified BerhadcoreStrategic or Co-development Partner · 6 May 2025Cyclacel Pharmaceuticals entered into a Share Exchange Agreement with FITTERS Diversified Berhad to acquire its subsidiary Fitters Sdn. Bhd. as a wholly-owned subsidiary. The transaction, expected to close by August 2025, involves Cyclacel issuing stock to FITTERS, with Cyclacel stockholders owning approximately 80% of the combined entity post-transaction.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Calithera Biosciences: Calithera develops small-molecule oncology drugs targeting tumor metabolism and immune regulation; comparable as a small-cap clinical-stage oncology developer that has navigated financing-driven dilution similar to BGMS.
• Tragara Pharmaceuticals: Tragara is a clinical-stage oncology company whose lead program (capmatinib/HGF/MET axis and earlier PLK1 work) and overall positioning as a small-cap cancer therapeutics developer make it closely comparable to BGMS's Plogosertib PLK1 program.
• Aprea Therapeutics: Aprea is a clinical-stage oncology company focused on small-molecule cancer therapies; its micro-cap public status and early-to-mid-stage pipeline parallel BGMS's clinical positioning with Plogosertib.
• DelMar Pharmaceuticals: DelMar is a clinical-stage oncology developer focused on novel cancer therapies; it matches BGMS on size, listing profile, and dependence on capital markets to advance a single clinical-stage oncology asset.
• Onconova Therapeutics: Onconova is a clinical-stage biopharmaceutical company developing small-molecule oncology candidates (e.g., rigosertib) — a near-identical micro-cap clinical-oncology profile to BGMS in scale, modality and stage.
• BioXcel Therapeutics: BioXcel is a clinical-stage biopharmaceutical company developing small-molecule therapies in oncology and neuroscience; comparable as a small-cap, publicly listed, clinical-stage developer with multiple shots on goal.
• Mateon Therapeutics: Mateon is a clinical-stage immuno-oncology / small-molecule developer; it is a comparable micro-cap public peer with a similarly narrow clinical pipeline and ongoing financing needs.
• Genprex: Genprex is a clinical-stage oncology company developing gene- and small-molecule-based cancer therapies; it is comparable to BGMS as a micro-cap, publicly listed, clinical-stage oncology developer dependent on periodic equity raises.
• Rigel Pharmaceuticals: Rigel develops small-molecule drugs in oncology and hematology, including cell-cycle-adjacent targets; as a small-cap commercial-stage oncology peer it shares BGMS's target-class focus and clinical-stage commercialization trajectory.

Emerging players

• Nerviano Medical Sciences: Nerviano is an oncology-focused discovery and development company with deep expertise in cell-cycle and kinase targets (including PLK inhibitors such as volasertib); it is comparable as an emerging player in the same PLK1 / cell-cycle chemistry space that underpins Plogosertib.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cyclacel-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds16 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyclacel Pharmaceuticals